QQ客服 官方微博 反馈留言

	Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years
	Zhang, Chi; Zhang, Fan; Liang, Guanzhao; Zeng, Xianshang; Yu, Weiguang; Jiang, Zhidao; Ma, Jie; Zhao, Mingdong; Xiong, Min; Gui, Keke
刊名	BMC MUSCULOSKELETAL DISORDERS
	2018
卷号	19
关键词	Denosumab Zoledronic acid Breast cancer Symptomatic skeletal event Outcome analyses
ISSN号	1471-2474
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3535854
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Zhang, Chi,Zhang, Fan,Liang, Guanzhao,et al. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years[J]. BMC MUSCULOSKELETAL DISORDERS,2018,19.
APA	Zhang, Chi.,Zhang, Fan.,Liang, Guanzhao.,Zeng, Xianshang.,Yu, Weiguang.,...&Ji, Weiping.(2018).Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years.BMC MUSCULOSKELETAL DISORDERS,19.
MLA	Zhang, Chi,et al."Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3years".BMC MUSCULOSKELETAL DISORDERS 19(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。